PharmaCyte Biotech, Inc.PMCB

Market cap

$16.94M

P/E ratio

	Apr 30, 2012	Apr 30, 2013	Apr 30, 2014	Apr 30, 2015	Apr 30, 2016	Apr 30, 2017	Apr 30, 2018	Apr 30, 2019	Apr 30, 2020	Apr 30, 2021	Apr 30, 2022	Apr 30, 2023
Revenue	66,558	12,160	-	-	-	-	-	-	-	-	-	-
Research and development costs	-	-	-	3	1	1	2	460,052	301,221	916,249	690,937	468,536
Compensation expense	-	-	14	6	2	2	2	2	2	1	2	1
Director fees	-	-	768,000	18,000	45,000	65,500	326,540	406,812	316,892	273,230	256,490	951,347
Legal and professional	327,158	284,510	1	884,346	458,397	478,674	617,358	299,963	459,146	586,207	809,489	3
General and administrative	416,171	617,271	2	3	2	744,796	2	1	1	418,145	1	1
Total operating expenses	2	2	19	14	6	4	7	4	4	4	4	6
Loss from operations	-	-1,684,361	-18,979,142	-13,695,489	-6,073,133	-4,442,146	-6,981,429	-4,100,629	-3,826,395	-3,622,981	-4,392,014	-6,455,494
Interest income	-	-	-	-	-	-	-	-	-	-	157,645	2
Interest expense	241,246	112,662	5,030	4,938	1,191	1,539	-	-	453	3,046	509	-
Other income (expense), net	-	-	-8,274,878	3	9,349	-1,539	152,588	33,401	-493	71,745	-	202,002
Total other income, net	-	86,259	-	-	-	-	-	-	-	-	152,853	2
Net loss	-1,899,312	-1,598,102	-27,254,020	-10,854,509	-6,063,784	-4,443,685	-6,828,841	-4,067,228	-3,826,888	-3,551,236	-4,239,161	-4,315,993
Basic loss per share	0.01	-	-0.05	-	-	-	-	-	-	-	-0.27	-0.22
Diluted loss per share	-	-	-	-	-	-	-	-	-	-	-0.27	-0.22